Headache

To define headache characteristics and evolution in relation to COVID-19 and its inflammatory response. This is a prospective study, comparing clinical data and inflammatory biomarkers of COVID-19 patients with and without headache, recruited at the Emergency Room. We compared baseline with 6-week f...

Descripción completa

Detalles Bibliográficos
Autores: Caronna, Edoardo|||0000-0001-5525-0267, Ballvé, Alejandro, Llauradó, Arnau|||0000-0002-4655-6157, Gallardo López, Victor José|||0000-0002-3042-2007, Ariton, Diana María|||0000-0002-6035-5466, Lallana, Sofía|||0000-0002-5999-9889, López Maza, Samuel|||0000-0003-3660-2604, Olivé-Gadea, Marta|||0000-0003-4637-1598, Quibus, Laura, Restrepo, Juan Luis|||0000-0002-6332-6126, Rodrigo-Gisbert, Marc|||0000-0002-7953-3795, Vilaseca, Andreu|||0000-0001-8147-8505, Hernandez Gonzalez, Manuel, Martínez Gallo, Mónica|||0000-0002-7340-2161, Alpuente, Alicia|||0000-0001-5296-9401, Torres-Ferrús, Marta|||0000-0003-2856-4134, Pujol Borrell, Ricard, Álvarez Sabín, José|||0000-0002-8054-9209, Pozo-Rosich, Patricia|||0000-0003-0796-4702
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:238641
Acceso en línea:https://ddd.uab.cat/record/238641
https://dx.doi.org/urn:doi:10.1177/0333102420965157
Access Level:acceso abierto
Palabra clave:Headache
COVID-19
SARS-CoV-2
Prognosis
Loss of smell
Descripción
Sumario:To define headache characteristics and evolution in relation to COVID-19 and its inflammatory response. This is a prospective study, comparing clinical data and inflammatory biomarkers of COVID-19 patients with and without headache, recruited at the Emergency Room. We compared baseline with 6-week follow-up to evaluate disease evolution. Of 130 patients, 74.6% (97/130) had headache. In all, 24.7% (24/97) of patients had severe pain with migraine-like features. Patients with headache had more anosmia/ageusia (54.6% vs. 18.2%; p < 0.0001). Clinical duration of COVID-19 was shorter in the headache group (23.9 ± 11.6 vs. 31.2 ± 12.0 days; p = 0.028). In the headache group, IL-6 levels were lower at the ER (22.9 (57.5) vs. 57.0 (78.6) pg/mL; p = 0.036) and more stable during hospitalisation. After 6 weeks, of 74 followed-up patients with headache, 37.8% (28/74) had ongoing headache. Of these, 50% (14/28) had no previous headache history. Headache was the prodromal symptom of COVID-19 in 21.4% (6/28) of patients with persistent headache (p = 0.010). Headache associated with COVID-19 is a frequent symptom, predictive of a shorter COVID-19 clinical course. Disabling headache can persist after COVID-19 resolution. Pathophysiologically, its migraine-like features may reflect an activation of the trigeminovascular system by inflammation or direct involvement of SARS-CoV-2, a hypothesis supported by concomitant anosmia.

Similares en LA Referencia